Janssen submits NDA for apalutamide in non-metastatic castration-resistant prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Janssen Biotech Inc. said it has submitted a New Drug Application to the FDA for apalutamide, an investigational, next generation oral androgen receptor inhibitor for men with non-metastatic castration-resistant prostate cancer. Currently, there are no FDA approved treatments for patients with non-metastatic CRPC.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe